Logo image of SLNO

SOLENO THERAPEUTICS INC (SLNO) Stock Fundamental Analysis

NASDAQ:SLNO - Nasdaq - US8342033094 - Common Stock - Currency: USD

68.93  -1.05 (-1.5%)

After market: 68.93 0 (0%)

Fundamental Rating

2

Overall SLNO gets a fundamental rating of 2 out of 10. We evaluated SLNO against 568 industry peers in the Biotechnology industry. While SLNO seems to be doing ok healthwise, there are quite some concerns on its profitability. SLNO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SLNO has reported negative net income.
In the past year SLNO has reported a negative cash flow from operations.
SLNO had negative earnings in each of the past 5 years.
SLNO had a negative operating cash flow in each of the past 5 years.
SLNO Yearly Net Income VS EBIT VS OCF VS FCFSLNO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

With a Return On Assets value of -53.13%, SLNO perfoms like the industry average, outperforming 45.07% of the companies in the same industry.
SLNO's Return On Equity of -71.74% is in line compared to the rest of the industry. SLNO outperforms 55.99% of its industry peers.
Industry RankSector Rank
ROA -53.13%
ROE -71.74%
ROIC N/A
ROA(3y)-55.18%
ROA(5y)-58.08%
ROE(3y)-109.68%
ROE(5y)-111.38%
ROIC(3y)N/A
ROIC(5y)N/A
SLNO Yearly ROA, ROE, ROICSLNO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

SLNO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLNO Yearly Profit, Operating, Gross MarginsSLNO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, SLNO has more shares outstanding
SLNO has more shares outstanding than it did 5 years ago.
The debt/assets ratio for SLNO is higher compared to a year ago.
SLNO Yearly Shares OutstandingSLNO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
SLNO Yearly Total Debt VS Total AssetsSLNO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

SLNO has an Altman-Z score of 19.30. This indicates that SLNO is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 19.30, SLNO belongs to the best of the industry, outperforming 94.72% of the companies in the same industry.
A Debt/Equity ratio of 0.20 indicates that SLNO is not too dependend on debt financing.
The Debt to Equity ratio of SLNO (0.20) is worse than 69.89% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Altman-Z 19.3
ROIC/WACCN/A
WACCN/A
SLNO Yearly LT Debt VS Equity VS FCFSLNO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

A Current Ratio of 15.68 indicates that SLNO has no problem at all paying its short term obligations.
SLNO has a better Current ratio (15.68) than 91.37% of its industry peers.
A Quick Ratio of 15.68 indicates that SLNO has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 15.68, SLNO belongs to the best of the industry, outperforming 91.37% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 15.68
Quick Ratio 15.68
SLNO Yearly Current Assets VS Current LiabilitesSLNO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

SLNO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -43.43%.
EPS 1Y (TTM)-43.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-284.85%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, SLNO will show a very strong growth in Earnings Per Share. The EPS will grow by 42.87% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y30.26%
EPS Next 2Y43.76%
EPS Next 3Y42.87%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SLNO Yearly Revenue VS EstimatesSLNO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2025 2026 2027 100M 200M 300M 400M
SLNO Yearly EPS VS EstimatesSLNO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -50 -100 -150

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SLNO. In the last year negative earnings were reported.
Also next year SLNO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SLNO Price Earnings VS Forward Price EarningsSLNO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLNO Per share dataSLNO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

SLNO's earnings are expected to grow with 42.87% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.76%
EPS Next 3Y42.87%

More info and screens

0

5. Dividend

5.1 Amount

SLNO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SOLENO THERAPEUTICS INC

NASDAQ:SLNO (4/21/2025, 8:00:02 PM)

After market: 68.93 0 (0%)

68.93

-1.05 (-1.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-27 2025-02-27/amc
Earnings (Next)05-13 2025-05-13/amc
Inst Owners114.62%
Inst Owner Change0.88%
Ins Owners2.48%
Ins Owner Change-10.09%
Market Cap3.16B
Analysts86.67
Price Target98.37 (42.71%)
Short Float %11.34%
Short Ratio9.66
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-97.22%
Min EPS beat(2)-186.49%
Max EPS beat(2)-7.96%
EPS beat(4)1
Avg EPS beat(4)-61.22%
Min EPS beat(4)-186.49%
Max EPS beat(4)6.6%
EPS beat(8)2
Avg EPS beat(8)-42.48%
EPS beat(12)5
Avg EPS beat(12)-24.3%
EPS beat(16)7
Avg EPS beat(16)-18.52%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)29.89%
PT rev (3m)29.89%
EPS NQ rev (1m)0.15%
EPS NQ rev (3m)-12.97%
EPS NY rev (1m)-5.28%
EPS NY rev (3m)-9.51%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)-3.58%
Revenue NY rev (3m)0.02%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 12.9
P/tB 13.26
EV/EBITDA N/A
EPS(TTM)-4.26
EYN/A
EPS(NY)-2.97
Fwd EYN/A
FCF(TTM)-1.51
FCFYN/A
OCF(TTM)-1.51
OCFYN/A
SpS0
BVpS5.34
TBVpS5.2
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -53.13%
ROE -71.74%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-55.18%
ROA(5y)-58.08%
ROE(3y)-109.68%
ROE(5y)-111.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.2
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.97%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 15.68
Quick Ratio 15.68
Altman-Z 19.3
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)3.83%
Cap/Depr(5y)2.6%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-43.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-284.85%
EPS Next Y30.26%
EPS Next 2Y43.76%
EPS Next 3Y42.87%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-353.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-177.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-177.05%
OCF growth 3YN/A
OCF growth 5YN/A